Trials / Terminated
TerminatedNCT00607152
Rasburicase (Fasturtec) Registration Trial
A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Primary: To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related hyperuricemia in Chinese patients with leukemia or lymphoma. Secondary: To compare the efficacy and safety of Rasburicase versus allopurinol in Chinese patients stratified according to disease (leukemia or lymphoma ).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasburicase | 0.20mg/kg per day IV |
| DRUG | Allopurinol | 100mg tablets |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-02-05
- Last updated
- 2014-05-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00607152. Inclusion in this directory is not an endorsement.